Polycythemia Vera: Clinical Trials

276 trials for Polycythemia Vera, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

147 completed, 36 recruiting, 32 terminated, 20 active not recruiting. 120 Phase 2, 71 Phase 1, 35 Phase 3, 24 Not applicable, 3 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2120Completed 71, Terminated 15, Active not recruiting 11, Recruiting 11, Withdrawn 6, Not yet recruiting 3, Unknown 3
Phase 171Completed 42, Terminated 8, Recruiting 7, Withdrawn 6, Unknown 4, Active not recruiting 3, Not yet recruiting 1
Phase 335Completed 20, Recruiting 7, Active not recruiting 3, Terminated 3, Not yet recruiting 1, Unknown 1
Not applicable24Completed 10, Not yet recruiting 5, Terminated 4, Recruiting 3, Unknown 1, Withdrawn 1
Early Phase 13Completed 1, Terminated 1, Withdrawn 1
Phase 43Active not recruiting 1, Terminated 1, Withdrawn 1

Follow Polycythemia Vera: new trials by email Literature Review of Polycythemia Vera trials Research Report on Polycythemia Vera

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Rusfertide in Adults With Polycythemia Vera in China
Rusfertide - Polycythemia Vera
Phase 2Not yet recruitingTakeda242027-03-012026-08-28
WELL-MPN: A Digital Lifestyle App for Patients With MPNs
WELL-MPN Digital App - Myeloproliferative Neoplasms (MPNs)
Not applicableNot yet recruitingBrigham and Women's Hospital752027-01-012026-09-29
A Study to Better Understand the Diagnosis and Treatment of Polycythaemia Vera
No Intervention - Polycythemia Vera
Not yet recruitingTakeda902026-12-012026-10-09
A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera
AG-236, Placebo - Polycythemia Vera
Phase 2 / Phase 3Not yet recruitingAgios Pharmaceuticals, Inc.2452026-11-012026-10-13
A Study of Ropeg-Interferon in People With Polycythemia Vera
Ropeginterferon - Polycythemia Vera (PV), JAK2 Mutation
Phase 2Not yet recruitingMemorial Sloan Kettering Cancer Center552026-10-302026-10-21
A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025).
Bomedemstat, Ruxolitinib, Ropeginterferon alfa-2b - Polycythemia Vera
Phase 2 / Phase 3RecruitingMerck Sharp & Dohme LLC3802026-10-212026-10-21
Standardized Documentation and Assessments for Polycythemia Vera: A Quality Improvement Initiative
Standardized progress note - Polycythemia Vera
Not applicableNot yet recruitingMassachusetts General Hospital322026-08-052026-07-29
ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia
Participants will take part in a 12-week exercise program that includes aerobic and resistance training, tailored to their individual fitness level and clinical condition. - Myeloproliferative Disease, Polycythemia Vera
Not applicableNot yet recruitingCarmen Fava252026-08-012026-04-09
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
Ropeginterferon alfa-2b, Phlebotomy and aspirin - Polycythemia Vera, Myeloproliferative Neoplasm
Phase 4WithdrawnPharmaEssentia2026-08-012026-07-31
A Study of Rusfertide in Japanese Adults With Polycythemia Vera
Rusfertide - Polycythemia Vera
Phase 2RecruitingTakeda92026-07-142026-10-02
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Sapablursen, Placebo - Polycythemia Vera
Phase 3RecruitingOno Pharmaceutical Co., Ltd.2502026-05-252026-10-21
Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers
ZE74-0282 - Polycythemia Vera (PV), Myelofibrosis (MF)
Phase 1Not yet recruitingEilean Therapeutics602026-05-152026-04-14
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
INCA036978, Standard disease-directed therapy - Myeloproliferative Neoplasms
Phase 1RecruitingIncyte Corporation2182026-05-112026-10-09
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF)
Phase 1RecruitingPrelude Therapeutics Incorporated1002026-04-292026-10-01
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
Gecacitinib Hydrochloride Tablets;Pegylated interferon alfa-2b - Polycythemia Vera (PV)
Not applicableRecruitingDuan Minghui302026-04-022026-06-24
Potential Biological and Physiological Determinants for Exercice in Patients With Polycythemia Vera
Research samples blood viscosity and viscoelasticity: - Polycythemia, Polycythemia Vera (PV)
Not applicableNot yet recruitingHospices Civils de Lyon542026-01-012026-01-15
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Polycythemia Vera, Thrombocythemia
RecruitingFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS6782025-12-012026-07-09
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Polycythemia Vera, ET (Essential Thrombocythemia)
RecruitingMPN Research Foundation50002025-09-262026-01-23
Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg - Polycythemia Vera (PV)
Phase 2RecruitingChengdu Zenitar Biomedical Technology Co., Ltd602025-09-232026-08-14
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm
Phase 2RecruitingNational Cancer Institute (NCI)782025-08-142026-09-30

Showing 20 of 276. Sign in to see all of them.

Narrower conditions

Primary Myelofibrosis (181)  ·  Thrombocythemia, Essential (174)  ·  Myeloproliferative Disorders (144)  ·  Leukemia, Myeloid, Acute (88)  ·  Leukemia, Myelomonocytic, Chronic (85)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (80)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (78)  ·  Myelodysplastic Syndromes (72)  ·  Multiple Myeloma (71)  ·  Leukemia (67)  ·  Lymphoma, Follicular (67)  ·  Lymphoma, Large B-Cell, Diffuse (64)  ·  Lymphoma, Mantle-Cell (64)  ·  Lymphoma, Non-Hodgkin (64)

Broader conditions

Hemic and Lymphatic Diseases (276)  ·  Neoplasms by Site (276)  ·  Bone Marrow Neoplasms (275)  ·  Hematologic Neoplasms (272)  ·  Bone Marrow Diseases (266)  ·  Hematologic Diseases (262)  ·  Neoplasms (261)  ·  Blood Platelet Disorders (180)  ·  Hemorrhagic Disorders (176)  ·  Blood Coagulation Disorders (174)  ·  Thrombocytosis (169)  ·  Myeloproliferative Disorders (132)  ·  Pathological Conditions, Signs and Symptoms (112)  ·  Neoplasms by Histologic Type (111)  ·  Pathologic Processes (109)

Interventions

fludarabine phosphate (29)  ·  ruxolitinib (29)  ·  Peripheral Blood Stem Cell Transplantation (26)  ·  Cyclophosphamide (25)  ·  Busulfan (21)  ·  Tacrolimus (16)  ·  Whole-Body Irradiation (15)  ·  Mycophenolic Acid (14)  ·  Methotrexate (13)  ·  Cyclosporine (12)  ·  Antilymphocyte Serum (11)  ·  Hydroxyurea (11)  ·  Aspirin (9)  ·  Filgrastim (8)  ·  fludarabine (8)

Sponsors

M.D. Anderson Cancer Center (16)  ·  National Cancer Institute (NCI) (13)  ·  Novartis Pharmaceuticals (12)  ·  Fred Hutchinson Cancer Center (11)  ·  Incyte Corporation (6)  ·  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS (5)  ·  Icahn School of Medicine at Mount Sinai (5)  ·  Italfarmaco (5)  ·  Mayo Clinic (5)  ·  Ronald Hoffman (5)  ·  AOP Orphan Pharmaceuticals AG (4)  ·  City of Hope Medical Center (4)  ·  European Organisation for Research and Treatment of Cancer - EORTC (4)  ·  Memorial Sloan Kettering Cancer Center (4)  ·  Northwestern University (4)

Countries

United States (177)  ·  Italy (43)  ·  France (37)  ·  Germany (33)  ·  United Kingdom (27)  ·  Canada (23)  ·  Australia (19)  ·  Belgium (18)  ·  Spain (18)  ·  Poland (14)  ·  Hungary (13)  ·  China (11)  ·  Israel (11)  ·  Japan (10)  ·  Netherlands (10)

Top investigators

Ronald Hoffman, MD (7)  ·  John Mascarenhas, MD (6)  ·  Alessandro Rambaldi, MD (4)  ·  Ruben A. Mesa, MD (4)  ·  Heinz Gisslinger, MD (3)  ·  Jorge Cortes, MD (3)  ·  Srdan Verstovsek, MD (3)  ·  Ayalew Tefferi, MD (2)  ·  Charles A. Linker, MD (2)  ·  Gabriela Hobbs, MD (2)

Results publications

PMID 29246923, PMID 29396713, PMID 32499241, PMID 33275766, PMID 40313042, PMID 40775758, PMID 41890273, PMID 11373690, PMID 11468154, PMID 15459300, PMID 15570084, PMID 16709929, PMID 17397698, PMID 18650451, PMID 18698002, PMID 19841031, PMID 20651074, PMID 20843246, PMID 22259028, PMID 22480131, PMID 22718840, PMID 23216616, PMID 23358983, PMID 23682558, PMID 23890523, PMID 24362550, PMID 24474568, PMID 24903629, PMID 25047979, PMID 25563429, PMID 25629741, PMID 25762180, PMID 25939704, PMID 26088933, PMID 26113113, PMID 26175532, PMID 26210442, PMID 26261238, PMID 26332546, PMID 26700120, PMID 26700123, PMID 26853648, PMID 27020837, PMID 27102499, PMID 27291777, PMID 27479177, PMID 27916398, PMID 28193568, PMID 28291640, PMID 28482711

NIH funding

P01CA108671 (7), P30CA015083 (5), P30CA006973 (4), 2014 (3), P01CA018029 (3), P30CA015704 (3), P30CA016086 (3), P30CA033572 (3), 2023 (2), P01CA015396 (2), P30CA016672 (2), P30CA060553 (2), P30CA068485 (2), P30CA072720 (2), U01CA062491 (2)